Ravoxertinib gdc-0994
Tīmeklis2024. gada 9. marts · Ravoxertinib also known as GDC-0994 and RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential … http://www.fluoroprobe.com/archives/tag/%e9%bb%91%e9%85%9a
Ravoxertinib gdc-0994
Did you know?
Tīmeklis2024. gada 7. aug. · 分析GDC-0994与ERK2的共晶复合物（图4），可以发现2- 氨基嘧啶结构能够与铰链区的Met108、Leu107形成氢键作用，吡啶酮羰基能够通过水分子与门控残基Gln105和催化残基Lys54形成相互作用，羟甲基部分可以同时与Asp167 和Asn154形成氢键作用，氟氯取代的苯基能够结合到 ... TīmeklisRavoxertinib (GDC-0994) also inhibits p90RSK with an IC 50 of 12 nM. Ravoxertinib (GDC-0994) is highly selective for ERK1 and ERK2, with biochemical potency of 1.1 …
TīmeklisGenentech is developing ravoxertinib (GDC 0994), a selective inhibitor of mitogen-activated protein kinase 1/3 (MAPK1/3), for the treatment of solid tumours. Tīmeklis2024. gada 17. janv. · Ravoxertinib盐酸盐生物活性. Ravoxertinib hydrochloride (GDC-0994 hydrochloride) 是一种可口服的 ERK 抑制剂，对 ERK1 和 ERK2 的 IC50 值分别为 6.1 nM 和 3.1 nM。. Ravoxertinib也抑制p90RSK，IC50为12 nM [1]。. Ravoxertinib对ERK1和ERK2具有高度选择性，生化能力分别为1.1 nM和0.3 nM [2]。. 在CD-1小鼠 ...
TīmeklisRavoxertinib (GDC-0994) New. Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1. SP600125. TīmeklisGenentech is developing ravoxertinib (GDC 0994), a selective inhibitor of mitogen-activated protein kinase 1/3 (MAPK1/3), for the treatment of solid tumours. ... GDC-0994; RG-7842 Latest Information Update: 02 Aug 2024. Price : $50 * Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. ...
Tīmeklis2016. gada 23. jūn. · Simultaneous targeting of multiple nodes in the pathway, such as MEK and ERK, offers the prospect of enhanced efficacy as well as reduced potential for acquired resistance. Described herein is the discovery and characterization of GDC-0994 (22), an orally bioavailable small molecule inhibitor selective for ERK kinase …
TīmeklisRavoxertinib 是可口服的ERK激酶抑制剂，抑制ERK1和ERK2的IC50分别为 6.1 和 3.1 nM。 ... GDC-0994（p.o.）可抑制体内ERK磷酸化和ERK介导的信号转导通路的激活,随后阻碍ERK依赖性肿瘤细胞增殖和存活.在体外癌症模型中,GDC-0994（p.o.）可造成显著的多重单剂量活性,包括BRAF突变 ... eight basic types of icingsTīmeklisGDC-0994 is an effective and orally available ERK1/2 inhibitor (IC50: 1.1/0.3 nM). All products from TargetMol are for Research Use Only. Not for Human or Veterinary or … follow up email for contract signingTīmeklisGDC-0994抑制ERK磷酸化和ERK介导的信号转导通路的激活。. 库存： 现货. 规格. 价格. 数量. 5 mg. ￥ 800.00. 10 mg. ￥ 1,000.00. eightbearTīmeklisDescription: Ravoxertinib (formerly known as GDC0994; RG7842) is a novel, potent, orally bioavailable inhibitor of extracellular signal-regulated kinase (ERK1/2) with … eight baseTīmeklisPexmetinib (ARRY-614) New Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1. SB239063 New. SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.. Ravoxertinib … eight basic colors in orderTīmeklis2015. gada 29. maijs · This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or metastatic solid tumors for which standard therapies either do not exist or have proven … eight bathTīmeklisChemFaces is Reference Standard and high-purity Natural Products Manufacturer of Ravoxertinib (GDC-0994)(CFN60296) CAS no.:1453848-26-4 Info: Read More ChemFaces is a professional high-purity natural products manufacturer. eight bath hotel